Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

This study is testing a new drug called cabotamig (ARB202) for people with advanced gastrointestinal cancers including colorectal, pancreatic, gastric, liver, or bile duct cancers. The drug targets a protein called CDH17, which is found on many gastrointestinal cancer cells. **You may be eligible if...** - You have been diagnosed with colorectal, pancreatic, gastric, primary liver, or bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed - Standard treatments have failed or no longer work - Your tumor has been tested and expresses the CDH17 protein (except for colorectal cancer patients who may not need this test) **You may NOT be eligible if...** - Your tumor does not express CDH17 (for most cancer types) - You have not tried standard treatments first - You have serious organ dysfunction or other conditions that make the treatment unsafe Talk to your doctor to see if this trial is right for you.